J
Jan A. Burger
Researcher at University of Texas MD Anderson Cancer Center
Publications - 543
Citations - 33028
Jan A. Burger is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 83, co-authored 511 publications receiving 28306 citations. Previous affiliations of Jan A. Burger include University of Texas Health Science Center at Houston & University of Freiburg.
Papers
More filters
Journal ArticleDOI
Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)
Alessandra Tedeschi,Paul M. Barr,Tadeusz Robak,Carolyn Owen,Paolo Ghia,Osnat Bairey,Peter Hillmen,Nancy L. Bartlett,Jianyong Li,David Simpson,Sebastian Grosicki,Stephen Devereux,Helen McCarthy,Steven Coutre,Hang Quach,Gianluca Gaidano,Zvenyslava Maslyak,Don A. Stevens,Ann Janssens,Fritz Offner,Jiří Mayer,Michael O'Dwyer,Andrzej Hellmann,Anna Schuh,Tanya Siddiqi,Aaron Polliack,Constantine S. Tam,Michael J. Keating,Deepali Suri,Cathy Zhou,Fong Clow,Lori Styles,Danelle F. James,Thomas J. Kipps,Jan A. Burger +34 more
TL;DR: Byrd et al. as mentioned in this paper conducted a randomized, open-label phase 3 trial to evaluate efficacy and safety of single-agent ibr vs clb in treatment-naive older patients with CLL/SLL.
Journal ArticleDOI
Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study
Prithviraj Bose,David McCue,Nathan P. Wiederhold,Tapan M. Kadia,Gautam Borthakur,Farhad Ravandi,Musa Yilmaz,Koichi Takahashi,Philip A. Thompson,Naveen Pemmaraju,Naval Daver,Jan A. Burger,Jorge E. Cortes,Guillermo Garcia-Manero,Srdan Verstovsek,Marina Konopleva,Nitin Jain,Courtney D. DiNardo,Yesid Alvarado,Kiran Naqvi,Steven M. Kornblau,Alessandra Ferrajoli,William G. Wierda,Zeev Estrov,Christopher B. Benton,Lucia Masarova,Guillermo Montalban-Bravo,Koji Sasaki,Caitlin R. Rausch,Kayleigh Marx,Wei Qiao,Xuelin Huang,Carol Bivins,Sherry Pierce,Hagop M. Kantarjian,Dimitrios P. Kontoyiannis +35 more
TL;DR: This is an investigator-initiated, phase 2, single-arm, open-label trial of primary antifungal ppx with ISAV in neutropenic pts with AML/MDS, with the primary endpoint the incidence of proven/probable IFI.
Journal ArticleDOI
Successful Outcomes of Severe COVID-19 in Patient with Chronic Lymphocytic Leukemia: Diagnostic Challenges in Immunocompromised Hosts
Alexandre E. Malek,Cristina Gutierrez,Victor E. Mulanovich,Joshua Botdorf,Roy F. Chemaly,Shivan Shah,Brandi M McCall,Judd Melancon,Kelly K. McConn,Jovan Borjan,Issam I Raad,Jan A. Burger,Guillermo Garcia-Manero,Javier A. Adachi +13 more
TL;DR: This case highlights the importance of a comprehensive diagnostic approach of pneumonia in immunocompromised hosts, including timely and safe bronchoscopy, because of the broad differential diagnosis, more challenging with the current outbreak of COVID-19.
Journal ArticleDOI
Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL).
Sameer A. Parikh,William G. Wierda,Xavier Badoux,S. M. O'Brien,A. Ferrajoli,Stephan Faderl,Jan A. Burger,Susan Lerner,Hagop M. Kantarjian,Michael J. Keating +9 more
TL;DR: A historic comparison of pts with Rai III/IV CLL treated with front-line FC versus FCR at an institution is reported, showing that treatment with FCR was associated with significant improvement in progression-free survival and overall survival in previously untreated patients with CLL.
Journal ArticleDOI
Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies.
Candida Vitale,Lorenzo Falchi,Maria Ciccone,Jan A. Burger,Naveen Pemmaraju,Gautam Borthakur,William G. Wierda,Michael J. Keating,Alessandra Ferrajoli +8 more
TL;DR: Single-agent ofatumumab is a well-tolerated and effective therapeutic approach for treatment-naïve older patients with CLL; it can be safely administered to patients with significant comorbidities and other cancer diagnoses.